Publications

The AMR Accelerator calls to action:
European capacity for antibiotic R&D requires long-term funding

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9

All Publications COMBINE ERA4TB GNA NOW PrIMAVeRa RespiriNTM RespiriTB TRIC-TB UNITE4TB

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Leclerc QJ, Duval A, Guillemot D, Opatowski L, Temime L. Using contact network dynamics to implement efficient interventions against pathogen spread in hospital settings: A modelling study. PLOS Medicine. 2024;21(7):e1004433. doi:10.1371/journal.pmed.1004433
Weston DJ, Thomas S, Boyle GW, Pieren M. Alpibectir: Early Qualitative and Quantitative Metabolic Profiling from a First-Time-in-Human Study by Combining 19 F-NMR (Nuclear Magnetic Resonance), 1 H-NMR, and High-Resolution Mass Spectrometric Analyses. Drug Metabolism and Disposition. 2024;52(8):858-874. doi:10.1124/dmd.124.001562
Nagar S, Nicholls D, Dawoud D, et al. A systematic review of economic evaluations of pharmacological treatments for active tuberculosis. Frontiers in Public Health. 2024;12:1201512. doi:10.3389/FPUBH.2024.1201512
Pieren M, Abáigar Gutiérrez-Solana A, Antonijoan Arbós RM, et al. First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug. Journal of Antimicrobial Chemotherapy. 2024;79(6):1353-1361. doi:10.1093/jac/dkae107
Aguilar-Ayala DA, Fernando Sanz-García |, Marie |, et al. Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin. British Journal of Clinical Pharmacology. Published online April 17, 2024. doi:10.1111/BCP.16068
Pezzani MD, Arieti F, Rajendran NB, et al. Frequency of bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research and discovery of new therapies in Europe: a systematic review. Clinical Microbiology and Infection. 2024;30:S4-S13. doi:10.1016/j.cmi.2023.10.019
Robotham J v., Tacconelli E, Vella V, de Kraker MEA. Synthesizing pathogen- and infection-specific estimates of the burden of antimicrobial resistance in Europe for health-technology assessment: gaps, heterogeneity, and bias. Clinical Microbiology and Infection. 2024;30:S1-S3. doi:10.1016/j.cmi.2023.10.004
Kingston R, Vella V, Pouwels KB, et al. Excess resource use and cost of drug-resistant infections for six key pathogens in Europe: a systematic review and Bayesian meta-analysis. Clinical Microbiology and Infection. 2024;30:S26-S36. doi:10.1016/J.CMI.2023.12.013
Smiejkowska N, Oorts L, van Calster K, et al. A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors . Microbiology Spectrum. 2024;12(3). doi:10.1128/SPECTRUM.03723-23
Gillespie SH, DiNardo AR, Georghiou SB, et al. Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles. The Lancet Microbe. 2024;0(0). doi:10.1016/S2666-5247(24)00085-5
Villa S, de Colombani P, Dall’Olio L, Gargioni G, Raviglione M. Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis. BMJ Global Health. 2024;9(4):e014630. doi:10.1136/BMJGH-2023-014630
Dufault SM, Crook AM, Rolfe K, Phillips PPJ. A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies. Statistics in Medicine. 2024;43(3):501-513. doi:10.1002/SIM.9961

2023

Moraga P, Prieto P, Conradie A, et al. Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units. Clinical and Translational Science. 2023;16(12):2421-2428. doi:10.1111/CTS.13655
van Wijk RC, Lucía A, Sudhakar PK, et al. Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium. iScience. 2023;26(4). doi:10.1016/j.isci.2023.106411
Mockeliunas L, Faraj A, van Wijk RC, et al. Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development. Frontiers in Pharmacology. 2023;14:1150243. doi:10.3389/FPHAR.2023.1150243
Villar-Hernández R, Ghodousi A, Konstantynovska O, Duarte R, Lange C, Raviglione M. Tuberculosis: current challenges and beyond. Breathe. 2023;19(1). doi:10.1183/20734735.0166-2022
Hassoun-Kheir N, Buetti N, Olivier V, et al. Targeted mupirocin-based decolonization for Staphylococcus aureus carriers and the subsequent risk of mupirocin resistance in haemodialysis patients – a longitudinal study over 20 years. Journal of Hospital Infection. 2023;135:55-58. doi:10.1016/j.jhin.2023.01.019
Hu W, Koch BEV, Lamers GEM, Forn-Cuní G, Spaink HP. Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria. Frontiers in Immunology. 2023;13:1075473. doi:10.3389/FIMMU.2022.1075473
Saluzzo F, Adepoju VA, Duarte R, Phillips PPJ, Lange C. Treatment-shortening regimens for tuberculosis: updates and future priorities. Breathe. 2023;19(3):230028. doi:10.1183/20734735.0028-2023
Ness T, Van LH, Petermane I, et al. Rolling out new anti-tuberculosis drugs without diagnostic capacity. Breathe. 2023;19(2). doi:10.1183/20734735.0084-2023

2022
Vasiliu A, Saktiawati AMI, Duarte R, Lange C, Cirillo DM. Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries. Breathe. 2022;18(4). doi:10.1183/20734735.0226-2022
Mistretta M, Gangneux N, Manina G. Microfluidic dose–response platform to track the dynamics of drug response in single mycobacterial cells. Scientific Reports 2022 12:1. 2022;12(1):1-18. doi:10.1038/s41598-022-24175-9
Hassoun-Kheir N, Harbarth S. Estimating antimicrobial resistance burden in Europe—what are the next steps? The Lancet Public Health. 2022;7(11):e886-e887. doi:10.1016/S2468-2667(22)00250-X
Pantel L, Guérin F, Serri M, et al. Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species. Antimicrobial Agents and Chemotherapy. 2022;66(11):11. doi:10.1128/AAC.00776-22
Arrazuria R, Kerscher B, Huber KE, et al. Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections. Frontiers in Microbiology. 2022;13:988725. doi:10.3389/FMICB.2022.988725
Arrazuria R, Kerscher B, Huber KE, et al. Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents. Frontiers in Microbiology. 2022;13:988728. doi:10.3389/FMICB.2022.988728
Keutzer L, You H, Farnoud A, et al. Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin. Pharmaceutics. 2022;14(8):1530. doi:10.3390/PHARMACEUTICS14081530
Heyckendorf J, Georghiou SB, Frahm N, et al. Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clinical Microbiology Reviews. 2022;35(3). doi:10.1128/CMR.00227-21
de Kraker MEA, Harbarth S. Global burden of antimicrobial resistance: essential pieces of a global puzzle. The Lancet. 2022;399(10344):2347. doi:10.1016/S0140-6736(22)00940-0
Kilinç G, Walburg K v., Franken KLMC, et al. Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Frontiers in Cellular and Infection Microbiology. 2022;12:872361. doi:10.3389/FCIMB.2022.872361

2021
Kilinç G, Saris A, Ottenhoff THM, Haks MC. Host-directed therapy to combat mycobacterial infections*. Immunological Reviews. 2021;301(1):62-83. doi:10.1111/IMR.12951
Boeree MJ, Lange C, Thwaites G, et al. UNITE4TB: a new consortium for clinical drug and regimen development for TB. International Journal of Tuberculosis and Lung Disease. 2021;25(11):886-889. doi:10.5588/IJTLD.21.0515

2020
Thacker V v., Dhar N, Sharma K, Barrile R, Karalis K, McKinney JD. A lung-on-chip model of early M. tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. eLife. 2020;9:1-73. doi:10.7554/ELIFE.59961
Faraj A, Clewe O, Svensson RJ, Mukamolova G v., Barer MR, Simonsson USH. Difference in Persistent Tuberculosis Bacteria between In Vitro and Sputum from Patients: Implications for Translational Predictions. Scientific Reports 2020 10:1. 2020;10(1):1-10. doi:10.1038/s41598-020-72472-y
Bekeredjian-Ding I. Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections. Frontiers in Immunology. 2020;11:533705. doi:10.3389/FIMMU.2020.01755

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Arrazuria R, Kerscher B, Huber KE, et al. Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections. Frontiers in Microbiology. 2022;13:988725. doi:10.3389/fmicb.2022.988725
Arrazuria R, Kerscher B, Huber KE, et al. Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents. Frontiers in Microbiology. 2022;13:988728. doi:10.3389/fmicb.2022.988728
Bekeredjian-Ding I. Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections. Frontiers in Immunology. 2020;11:533705. doi:10.3389/FIMMU.2020.01755

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Nagar S, Nicholls D, Dawoud D, et al. A systematic review of economic evaluations of pharmacological treatments for active tuberculosis. Frontiers in Public Health. 2024;12:1201512. doi:10.3389/FPUBH.2024.1201512
Aguilar-Ayala DA, Fernando Sanz-García |, Marie |, et al. Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin. British Journal of Clinical Pharmacology. Published online April 17, 2024. doi:10.1111/BCP.16068
Moraga P, Prieto P, Conradie A, et al. Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units. Clinical and Translational Science. 2023;16(12):2421-2428. doi:10.1111/CTS.13655
van Wijk RC, Lucía A, Sudhakar PK, et al. Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium. iScience. 2023;26(4). doi:10.1016/j.isci.2023.106411
Mistretta M, Gangneux N, Manina G. Microfluidic dose–response platform to track the dynamics of drug response in single mycobacterial cells. Scientific Reports 2022 12:1. 2022;12(1):1-18. doi:10.1038/s41598-022-24175-9
Thacker V v., Dhar N, Sharma K, Barrile R, Karalis K, McKinney JD. A lung-on-chip model of early M. tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. eLife. 2020;9:1-73. doi:10.7554/ELIFE.59961
Faraj A, Clewe O, Svensson RJ, Mukamolova G v., Barer MR, Simonsson USH. Difference in Persistent Tuberculosis Bacteria between In Vitro and Sputum from Patients: Implications for Translational Predictions. Scientific Reports 2020 10:1. 2020;10(1):1-10. doi:10.1038/s41598-020-72472-y

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Pantel L, Guérin F, Serri M, et al. Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species. Antimicrobial Agents and Chemotherapy. 2022;66(11):11. doi:10.1128/AAC.00776-22

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Leclerc QJ, Duval A, Guillemot D, Opatowski L, Temime L. Using contact network dynamics to implement efficient interventions against pathogen spread in hospital settings: A modelling study. PLOS Medicine. 2024;21(7):e1004433. doi:10.1371/journal.pmed.1004433
Pezzani MD, Arieti F, Rajendran NB, et al. Frequency of bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research and discovery of new therapies in Europe: a systematic review. Clinical Microbiology and Infection. 2024;30:S4-S13. doi:10.1016/j.cmi.2023.10.019
Robotham J v., Tacconelli E, Vella V, de Kraker MEA. Synthesizing pathogen- and infection-specific estimates of the burden of antimicrobial resistance in Europe for health-technology assessment: gaps, heterogeneity, and bias. Clinical Microbiology and Infection. 2024;30:S1-S3. doi:10.1016/j.cmi.2023.10.004
Kingston R, Vella V, Pouwels KB, et al. Excess resource use and cost of drug-resistant infections for six key pathogens in Europe: a systematic review and Bayesian meta-analysis. Clinical Microbiology and Infection. 2024;30:S26-S36. doi:10.1016/j.cmi.2023.12.013
Hassoun-Kheir N, Buetti N, Olivier V, et al. Targeted mupirocin-based decolonization for Staphylococcus aureus carriers and the subsequent risk of mupirocin resistance in haemodialysis patients – a longitudinal study over 20 years. Journal of Hospital Infection. 2023;135:55-58. doi:10.1016/j.jhin.2023.01.019
Hassoun-Kheir N, Harbarth S. Estimating antimicrobial resistance burden in Europe—what are the next steps? The Lancet Public Health. 2022;7(11):e886-e887. doi:10.1016/S2468-2667(22)00250-X
de Kraker MEA, Harbarth S. Global burden of antimicrobial resistance: essential pieces of a global puzzle. The Lancet. 2022;399(10344):2347. doi:10.1016/S0140-6736(22)00940-0

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Hu W, Koch BEV, Lamers GEM, Forn-Cuní G, Spaink HP. Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria. Frontiers in Immunology. 2023;13:1075473. doi:10.3389/FIMMU.2022.1075473
Kilinç G, Walburg K v., Franken KLMC, et al. Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Frontiers in Cellular and Infection Microbiology. 2022;12:872361. doi:10.3389/FCIMB.2022.872361
Kilinç G, Saris A, Ottenhoff THM, Haks MC. Host-directed therapy to combat mycobacterial infections*. Immunological Reviews. 2021;301(1):62-83. doi:10.1111/IMR.12951

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Smiejkowska N, Oorts L, van Calster K, et al. A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors . Microbiology Spectrum. 2024;12(3). doi:10.1128/SPECTRUM.03723-23
Kilinç G, Saris A, Ottenhoff THM, Haks MC. Host-directed therapy to combat mycobacterial infections*. Immunological Reviews. 2021;301(1):62-83. doi:10.1111/IMR.12951

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Weston DJ, Thomas S, Boyle GW, Pieren M. Alpibectir: Early Qualitative and Quantitative Metabolic Profiling from a First-Time-in-Human Study by Combining 19 F-NMR (Nuclear Magnetic Resonance), 1 H-NMR, and High-Resolution Mass Spectrometric Analyses. Drug Metabolism and Disposition. 2024;52(8):858-874. doi:10.1124/dmd.124.001562
Pieren M, Abáigar Gutiérrez-Solana A, Antonijoan Arbós RM, et al. First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug. Journal of Antimicrobial Chemotherapy. 2024;79(6):1353-1361. doi:10.1093/jac/dkae107

Fernow J, Olliver M, Couet W, et al. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Nature Reviews Drug Discovery 2024. Published online September 23, 2024. doi:10.1038/d41573-024-00138-9
Gillespie SH, DiNardo AR, Georghiou SB, et al. Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles. The Lancet Microbe. 2024;0(0). doi:10.1016/S2666-5247(24)00085-5
Villa S, de Colombani P, Dall’Olio L, Gargioni G, Raviglione M. Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis. BMJ Global Health. 2024;9(4):e014630. doi:10.1136/BMJGH-2023-014630
Dufault SM, Crook AM, Rolfe K, Phillips PPJ. A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies. Statistics in Medicine. 2024;43(3):501-513. doi:10.1002/SIM.9961
Mockeliunas L, Faraj A, van Wijk RC, et al. Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development. Frontiers in Pharmacology. 2023;14:1150243. doi:10.3389/FPHAR.2023.1150243
Villar-Hernández R, Ghodousi A, Konstantynovska O, Duarte R, Lange C, Raviglione M. Tuberculosis: current challenges and beyond. Breathe. 2023;19(1). doi:10.1183/20734735.0166-2022
Saluzzo F, Adepoju VA, Duarte R, Phillips PPJ, Lange C. Treatment-shortening regimens for tuberculosis: updates and future priorities. Breathe. 2023;19(3):230028. doi:10.1183/20734735.0028-2023
Ness T, Van LH, Petermane I, et al. Rolling out new anti-tuberculosis drugs without diagnostic capacity. Breathe. 2023;19(2). doi:10.1183/20734735.0084-2023
Vasiliu A, Saktiawati AMI, Duarte R, Lange C, Cirillo DM. Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries. Breathe. 2022;18(4). doi:10.1183/20734735.0226-2022
Keutzer L, You H, Farnoud A, et al. Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin. Pharmaceutics. 2022;14(8):1530. doi:10.3390/PHARMACEUTICS14081530
Heyckendorf J, Georghiou SB, Frahm N, et al. Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clinical Microbiology Reviews. 2022;35(3). doi:10.1128/CMR.00227-21
Boeree MJ, Lange C, Thwaites G, et al. UNITE4TB: a new consortium for clinical drug and regimen development for TB. International Journal of Tuberculosis and Lung Disease. 2021;25(11):886-889. doi:10.5588/IJTLD.21.0515
Thacker V v., Dhar N, Sharma K, Barrile R, Karalis K, McKinney JD. A lung-on-chip model of early M. tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. eLife. 2020;9:1-73. doi:10.7554/ELIFE.59961

The AMR Accelerator Results

Project Portfolio

Tools and Resources

Public Webinar Recordings

Publications

The AMR Accelerator calls to action: European capacity for antibiotic R&D requires long-term funding

2023

2022

2021

2020

The AMR Accelerator Results

The AMR Accelerator calls to action:
European capacity for antibiotic R&D requires long-term funding